• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

服用单剂量芬戈莫德后出现长时间且有症状的心动过缓。

Prolonged and symptomatic bradycardia following a single dose of fingolimod.

机构信息

Neurology, Max Planck Institute of Psychiatry, Munich, Germany.

出版信息

Mult Scler. 2013 Jan;19(1):126-8. doi: 10.1177/1352458512447596. Epub 2012 Jun 22.

DOI:10.1177/1352458512447596
PMID:22729989
Abstract

Fingolimod-related bradycardia is usually asymptomatic, reaches its nadir within 6 hours post-dose and recovers spontaneously. Here we report the case of a 30-year-old MS patient with vagotonia who developed symptomatic bradycardia with 33 beats per minute at nadir 39 hours after a single dose of fingolimod. Bradycardia was responsive to atropine, but returned within 2 hours. Overall, it took a week until the patient recovered. Extended monitoring is advised in patients with symptomatic bradycardia.

摘要

芬戈莫德相关的心动过缓通常无症状,在给药后 6 小时内达到最低点,并自发恢复。在此,我们报告了一例 30 岁多发性硬化症患者的病例,该患者在单次服用芬戈莫德后 39 小时出现迷走神经张力亢进导致的有症状心动过缓,最低点为 33 次/分钟。心动过缓对阿托品有反应,但在 2 小时内又恢复了。总体而言,患者需要一周时间才能恢复。对于有症状心动过缓的患者,建议进行延长监测。

相似文献

1
Prolonged and symptomatic bradycardia following a single dose of fingolimod.服用单剂量芬戈莫德后出现长时间且有症状的心动过缓。
Mult Scler. 2013 Jan;19(1):126-8. doi: 10.1177/1352458512447596. Epub 2012 Jun 22.
2
Delayed fingolimod-associated asystole.延迟性芬戈莫德相关心动过缓。
Mult Scler. 2011 Nov;17(11):1387-9. doi: 10.1177/1352458511410344. Epub 2011 Jun 7.
3
[Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].[芬戈莫德治疗多发性硬化症时心血管效应的临床意义]
Ideggyogy Sz. 2012 Nov 30;65(11-12):369-76.
4
Gilenya safety update: cardiac and macula.捷灵亚安全性更新:心脏与黄斑
Curr Opin Ophthalmol. 2012 Nov;23(6):457-9. doi: 10.1097/ICU.0b013e3283590bda.
5
Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.
Arch Dermatol. 2011 Aug;147(8):991-2. doi: 10.1001/archdermatol.2011.212.
6
The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.首次使用芬戈莫德治疗多发性硬化症时心血管并发症的实际经验。
Arq Neuropsiquiatr. 2014 Sep;72(9):712-4. doi: 10.1590/0004-282x20140102.
7
Delayed cardiac dysrhythmias after fingolimod administration.服用芬戈莫德后出现延迟性心脏心律失常。
Am J Emerg Med. 2015 Jul;33(7):987.e1-3. doi: 10.1016/j.ajem.2014.12.037. Epub 2014 Dec 26.
8
Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.盐酸芬戈莫德用于多发性硬化症患者的概述及安全性
Expert Opin Drug Saf. 2014 Jul;13(7):989-98. doi: 10.1517/14740338.2014.920820.
9
Fingolimod-associated amenorrhea: a report of three cases.芬戈莫德相关性闭经:三例报告。
Mult Scler. 2014 Oct;20(12):1662-4. doi: 10.1177/1352458514523497. Epub 2014 Feb 10.
10
Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.
Mult Scler. 2013 Oct;19(11):1551-2. doi: 10.1177/1352458513493035. Epub 2013 Jul 1.

引用本文的文献

1
Current understanding of cardiovascular autonomic dysfunction in multiple sclerosis.多发性硬化症中心血管自主神经功能障碍的当前认识
Heliyon. 2024 Aug 3;10(15):e35753. doi: 10.1016/j.heliyon.2024.e35753. eCollection 2024 Aug 15.
2
[Comorbidities in multiple sclerosis and their influence on the choice of treatment].[多发性硬化症的合并症及其对治疗选择的影响]
Rev Neurol. 2024 Mar 16;78(6):157-170. doi: 10.33588/rn.7806.2023277.
3
Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More.
炎症性肠病基于机制的治疗策略:细胞因子、细胞粘附分子、JAK抑制剂、肠道菌群等等。
Inflamm Intest Dis. 2019 Aug;4(3):79-96. doi: 10.1159/000500721. Epub 2019 Jul 9.
4
Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.多发性硬化症药物的作用机制及不良反应:一篇综述文章。第1部分。
Int J Physiol Pathophysiol Pharmacol. 2019 Aug 15;11(4):95-104. eCollection 2019.
5
Ventricular tachycardia after initiation of fingolimod.开始使用芬戈莫德后出现室性心动过速。
BMJ Case Rep. 2017 Sep 27;2017:bcr-2017-221819. doi: 10.1136/bcr-2017-221819.
6
Efficacy and Safety of Fingolimod in an Unselected Patient Population.芬戈莫德在未筛选患者群体中的疗效与安全性。
PLoS One. 2016 Jan 6;11(1):e0146190. doi: 10.1371/journal.pone.0146190. eCollection 2016.
7
AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.AKP-11——一种具有良好安全性的新型S1P1激动剂可减轻多发性硬化症大鼠模型中的实验性自身免疫性脑脊髓炎。
PLoS One. 2015 Oct 29;10(10):e0141781. doi: 10.1371/journal.pone.0141781. eCollection 2015.
8
Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.中枢自主神经功能障碍延缓芬戈莫德所致心率减慢的恢复。
PLoS One. 2015 Jul 6;10(7):e0132139. doi: 10.1371/journal.pone.0132139. eCollection 2015.
9
Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.多发性硬化症患者的体验与实践趋势——芬戈莫德的临床效用
Patient Prefer Adherence. 2015 May 21;9:685-93. doi: 10.2147/PPA.S57354. eCollection 2015.
10
Intermittent Atrioventricular Block following Fingolimod Initiation.芬戈莫德起始治疗后出现间歇性房室传导阻滞。
Case Rep Neurol Med. 2014;2014:191305. doi: 10.1155/2014/191305. Epub 2014 Aug 5.